EPRX
Eupraxia Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · CA
$8.40
+12.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 36.3M | 21.3M | 16.1M | 15.3M | 13.6M |
| SG&A Expense | 20.8M | 17.1M | 10.9M | 5.6M | 4.0M |
| General & Admin Expense | 20.8M | 17.1M | 10.9M | 5.6M | 4.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 57.1M | 38.4M | 27.0M | 21.0M | 17.6M |
| Cost and Expenses | 57.1M | 38.4M | 27.0M | 21.0M | 17.6M |
| Operating Income (EBIT) | (57.1M) | (38.4M) | (27.0M) | (21.0M) | (17.6M) |
| Non-Operating | |||||
| Interest Income | 3.3M | 1.4M | 1.2M | 649.8K | 431.8K |
| Interest Expense | — | — | 603.6K | 881.1K | 982.9K |
| Net Interest Income | 3.3M | 1.4M | 556.4K | (231.3K) | (551.1K) |
| Other Non-Op Income/Expense | 6.9M | (152.5K) | 1.3M | (814.9K) | (1.4M) |
| Non-Operating Income (excl Interest) | (6.9M) | 152.5K | (1.9M) | (66.1K) | 390.5K |
| EBT (Pre-Tax Income) | (50.2M) | (38.6M) | (25.7M) | (21.8M) | (19.0M) |
| Income Tax Expense | 55.0K | 19.1K | 1.8K | 27.4K | — |
| Bottom Line | |||||
| Net Income | (50.2M) | (38.6M) | (25.5M) | (21.2M) | (18.5M) |
| Earnings from Cont. Ops | (50.2M) | (38.6M) | (25.7M) | (21.8M) | (19.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (51.4M) | (38.6M) | (25.5M) | (21.2M) | (18.5M) |
| Per Share | |||||
| Basic EPS | ($0.99) | ($1.03) | ($0.76) | ($0.88) | ($0.96) |
| Diluted EPS | ($0.99) | ($1.03) | ($0.76) | ($0.88) | ($0.96) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 66.2M | 40.0M | 33.9M | 24.1M | 19.3M |
| Diluted Shares Outstanding | 66.2M | 40.0M | 33.9M | 24.1M | 19.3M |
| Profitability Metrics | |||||
| EBITDA | (49.9M) | (38.3M) | (25.0M) | (20.8M) | (17.9M) |
| D&A | 270.7K | 237.7K | 171.7K | 117.1K | 147.9K |
| EBIT | (50.2M) | (38.6M) | (25.1M) | (20.9M) | (18.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026